Compare DexCom, Inc. (DXCM) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lowe`s Companies Inc — how do they compare? DexCom, Inc. trades at $77.28 (market cap $28.06B), while Lowe`s Companies Inc trades at $214.67 (market cap $117.56B). The key difference: Lowe`s Companies Inc is far larger — about 4.2× DexCom, Inc.'s market cap, and Lowe`s Companies Inc pays a 2.38% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | LOW | |
|---|---|---|
Market Cap | $28.06B | $117.56B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $287.39 |
52-Week Low | $54.84 | $206.62 |
Enterprise Value | $27.03B | $159.31B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Lowe's Companies (LOW) trades at $213.81, up 2.94% on the day, with a bearish technical signal but strong analyst consensus. Recent earnings beats and a 7.51% net income margin highlight operational strength, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. The stock shows support near $205 and resistance at $215, with a consensus price target of $260.88 implying 22% upside. Dividend growth remains a key attraction, with the quarterly payout rising to $1.25.
LOW offers value with a P/E of 17.72 and bullish analyst sentiment (60.79% buy ratings), but faces risks from high debt levels and competitive pressures. The outlook hinges on execution in the professional segment and interest rate sensitivity, with near-term volatility expected around Q2 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
